BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

Core Insights - BridgeBio Oncology Therapeutics, Inc. (BBOT) announced two poster presentations for BBO-10203, a first-in-class oral small molecule targeting RAS:PI3Kα interaction, at the San Antonio Breast Cancer Symposium (SABCS) scheduled for December 9-12, 2025 [1] Group 1: Product Overview - BBO-10203 is designed to selectively block the interaction between RAS and PI3Kα, inhibiting RAS-driven PI3Kα-AKT signaling in tumors without causing hyperglycemia [4] - The drug is agnostic to the mutational status of RAS or PI3Kα, potentially treating tumors driven by KRAS or PI3Kα mutations, which are the most mutated oncogenes in human cancer [4] Group 2: Clinical Trials - BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ amplified or HR+/HER2- breast cancer, as well as KRAS mutant colorectal or non-small cell lung cancer [4] - The presentations at SABCS include data on the efficacy of BBO-10203 alone and in combination with fulvestrant or ribociclib in breast cancer models [6] Group 3: Company Background - BBOT is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics targeting RAS and PI3Kα malignancies, aiming to improve outcomes for patients with cancers driven by prevalent oncogenes [5]